• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.08% Nasdaq Up0.22%

    Ampio Pharmaceuticals, Inc. (AMPE)

    3.58 Up 0.11(3.17%) Nov 27, 1:02PM EST
    ProfileGet Profile for:
    Ampio Pharmaceuticals, Inc.
    373 Inverness Parkway
    Suite 200
    Englewood, CO 80112
    United States - Map
    Phone: 720-437-6500
    Fax: 720-437-6501
    Website: http://www.ampiopharma.com

    Index Membership:N/A
    Full Time Employees:23

    Business Summary 

    Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee; and Optina that is in Phase IIb clinical trial for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ampio Pharmaceuticals, Inc.

    Corporate Governance 
    Ampio Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Michael Macaluso , 64
    Founder, Chairman and Chief Exec. Officer
    Mr. Gregory A. Gould CPA, 49
    Chief Financial Officer, Corp. Sec. and Treasurer
    Dr. David Bar-Or M.D. , 66
    Chief Scientific Officer and Director
    Dr. Vaughan L. Clift M.D., 54
    Chief Regulatory Affairs Officer
    Mr. Philip H. Coelho , 71
    Director, Chairman of Compensation Committee, Chairman of Nominating & Governance Committee and Member of Audit Committee
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders